Abstract

ENSIFENTRINE: AN IN-DEPTH REVIEW OF ITS THERAPEUTIC PROFILE AND THE RATIONALE FOR ITS DEVELOPMENT IN THE TREATMENT OF RESPIRATORY CONDITIONS

P. Siva Gangadhar* and Dr. Spurthy Mithraw

.

Abstract

Background: In order to effectively control COPD, the innovative drug ensifentrine, an inhaled PED3/4 inhibitor, improves bronchodilation and lowers inflammation. This innovative dualmechanistic approach to COPD management sets it apart from traditional treatments that focus on just one of the mentioned mechanisms. Clinical research is being done on ensifentrine to determine how well it works to treat COPD symptoms. Objectives: To evaluate the efficacy of ensifentrine compared with placebo for lung function, symptoms, quality of life, and exacerbations in patients with COPD. Methods: The databases Embase, Cochrane Library, PubMed, and Google Scholar were used in a thorough search. The selected studies, which ranged from 2018 to 2024, examined the effects of ensifentrine on lung function, symptom alleviation, exacerbation, and quality of life through randomized controlled trials published in English. Conclusion: One promising medication for COPD sufferers is ensifentrine. Its combined strategy of bronchodilation and antiinflammation enhances lung function and quality of life. Nevertheless, more investigation is still required to determine its long-term safety and generalizability to other populations.

Keywords: Ensifentrine; nebulized therapy; dual PDE3 and PDE4 inhibitor, chronic obstructive pulmonary disease, clinical efficacy, drug development